Replay available

Anika Therapeutics (NASDAQ:ANIK) Q3 2021 Earnings Call

Anika Therapeutics (NASDAQ:ANIK) Q3 2021 earnings call, held 2021-11-04. Watch the replay and read the transcript on 6ix.

Thu, November 4, 2021 at 5:00 PMendedReplay
Anika Therapeutics (NASDAQ:ANIK) Q3 2021 Earnings Call
Company
Anika Therapeutics Inc. (NASDAQ:ANIK)
Period
Q3 2021 earnings call
Date
Thu, Nov 4, 2021, 5:00 PM ET
Replay
Watch the replay on this page · 45 min
Results news release
Anika Reports Third Quarter 2021 Financial Results · Thu, Nov 4, 2021

On 6ix: 6ix.com/event/anika-therapeutics-inc-anik-q3-2021-earnings-call

Replay

Transcript

Automated transcript · Written by software from the replay's audio. It can mishear names and figures; the replay is the record.

0:01 Good afternoon, ladies and gentlemen, and welcome to ANACA's third quarter 2021 earnings conference call. Today's conference is being recorded. I will now turn the call over to Mark Namaroff, Executive Director of Investor Relations and Corporate Communications. Please proceed.

0:17 Thank you. Good evening, everyone. Thank you for joining us for ANACA's third quarter conference call and webcast. Our Q3 earnings press release was issued after the close of the market today and is available on our investor relations website located at www.annika.com, as are the supplementary PowerPoint slides that will be used for the discussion today. With me on the call today are Dr. Cheryl Blanchard, President and Chief Executive Officer, and Mike Levitz, Executive Vice President and Chief Financial Officer and Treasurer. Please take a moment to open up the slide presentation and refer to slide number two. Before we begin, please understand that certain statements made during the call today constitute forward-looking statements as defined in the Securities Exchange Act of 1934. These statements are based on our current beliefs and expectations and are subject to certain risks and uncertainty, and the company's actual results could differ materially from any anticipated future results, performance, or achievements.

1:14 We make no obligation to update these statements should future financial data or events occur that differ from forward-looking statements presented today. Please also see our SEC filings and our most recent 10-K and 10-Q for more information about risk factors that could affect our performance. In addition, during the call we may refer to a number of adjusted or non-GAAP financial measures, which includes adjusted gross margin, adjusted EBITDA, adjusted net income, and adjusted earnings per share, which are used in addition to results presented in accordance with GAAP financial measures. We believe that non-GAAP measures provide an additional way of viewing aspects of our operations and performance but when considered with GAAP financial results and the reconciliation of GAAP measures, they provide an even more complete understanding of our business. The reconciliation of these adjusted non-GAAP financial results to the most comparable GAAP measurements are available at the end of the available presentation slides and in our third quarter press release.

2:13 And now I'll turn the call over to our President and CEO, Dr. Cheryl Blanchard.

2:17 Thanks, Mark. Good evening, everyone, and thanks for joining us. Please turn to slide three. Let me start by expressing my hope that everyone has been able to stay safe during these disruptive times and that we continue to prioritize the health and safety of our employees. I'll plan to review some highlights from the quarter and then Mike will go into the financial details and review the outlook for the remainder of 2021. I'm pleased to report another solid quarter with revenue up 25% over Q3 last year. primarily due to some COVID recovery and related timing of orders in our joint pain business. Our joint pain management business was up by 42% as last year the Q3 orders were the first to be impacted by COVID and this year on J&J MyTech order timing.

3:05 While there's lumpiness on a quarterly basis, the full year for this part of our business is coming in just as we expected as end market injection volumes have largely stabilized. OrthoVisc and MonoVisc combined remain the number one HA-Visco supplements in the US. Joint preservation and restoration revenue was lower by 4% over last year due to larger than expected COVID headwinds driven by the Delta variant causing rolling shutdowns at various sites of care. As a result, elective surgery volumes were lower than expected in the quarter. And even as the Delta spike begins to wane, we're seeing and expect to continue to see Healthcare worker shortages constrain surgery volumes in line with broader market reports.

3:50 As a reminder, Q3 of last year was where we saw a significant recovery from the first wave of COVID in our joint preservation and restoration business. Unfortunately, this year, we also saw industry events either dramatically scaled back or canceled and lack of access to surgical centers and hospitals that has had an ongoing impact on our ability to engage surgeons with our now fully integrated product portfolio. Another set of COVID challenges that we continue to carefully manage through are the supply chain issues that most industries are facing. Despite these challenges, we remain confident that we will deliver above market revenue growth in our joint preservation and restoration segment for 2021.

4:35 Adjusted gross margins for the quarter came in at 66% in line with our targets for the year Translating to positive adjusted EBITDA and positive operating cash flow. And we ended the quarter with $90 million of cash on the balance sheet. Our third quarter was highlighted with progress against our key milestones that we described during our investor day in June. During the quarter, we fully launched our wrist motion total wrist arthroplasty system, a key advancement expanding our portfolio beyond our existing hemi-wrist implant product. Our new product restores the natural wrist motion for arthritis patients and provides a motion-preserving solution, eliminating the need for joint fusion. The launch of this product at the American Society for Surgery of the Hand, or the ASSH annual meeting in September, received a lot of positive interest and attention from the hand and wrist surgical community.

5:30 Also during the quarter, we received an additional 510 clearance for Tactuset, our hyaluronic acid-based bone void filler, expanding its capability beyond treating insufficiency fractures to be used for the augmentation of hardware and supportive bone fragments during surgical procedures. This additional indication will expand Tactuset's addressable market, further cementing our strategy in the ASC-based sports medicine business by allowing surgeons to use Tactuset as an adjunct to suture anchor fixation when performing soft tissue repairs. These surgeries include rotator cuff repairs, were anchoring sutures into fragile or low quality bone can lead to inferior mechanical fixation and clinical outcomes. Once injected, Tacticet hardens and mimics the properties of normal trabecular bone initially and then remodels into healthy bone over time.

6:22 The use of Tacticet in this new indication has been shown to increase the pullout strength of a suture anchor by twofold, providing for a secure suture anchor fixation construct. This indication was launched in October and not only expands our addressable market, but it also allows us to define a new market where one doesn't currently exist. Additional indications for the use of Tacticet continue to evolve and we see this as a game-changing regenerative solution with a number of applications in the joint preservation space. Despite the growing concern over the spread of the Delta variant during the summer, the AAOS Annual Meeting was held in San Diego in August. The American Academy of Orthopedic Surgeons is the preeminent industry meeting for orthopedists and it was the first industry event that ANACA was able to attend as a fully integrated company and to really showcase our new story to the surgeon community.

7:16 Even though surgeon attendance was 80% lower than in prior years, feedback from surgeons who were there was very positive, reinforcing our portfolio strategy in joint preservation as procedures are transitioning more to the ASC. a trend that is only accelerating with COVID dynamics, especially in the strategic areas where we're focused along that early intervention continuum of care. On the talent front, we've continued to strengthen both our leadership team and board of directors with experienced leaders in the joint preservation space with the addition of two industry veterans. I'm happy to welcome Ann Nunes to the ANICA leadership team as our vice president of operations. Ann comes to Annika from Smith and Nephew where she held senior operational supply chain and transformation roles. Ann brings over 20 years of orthopedic and biotech operational experience and will focus her attention on optimizing Annika's global operations, driving improvements in supply chain management, and ensuring cost targets are met.

8:18 In addition, Monday we announced that our board of directors appointed Cheryl Connolly as an independent director. Cheryl comes with over 35 years of experience in orthopedics and healthcare, with 25 of those years spent at Zimmer, where she was last group president, Americas and Global Brand Management, and chief marketing officer, focusing on global brand management, marketing, sales, product development, and operations. I've known Cheryl for many years, and she brings in-depth commercial and operational experience to the board to help guide our strategy. Both Ann and Cheryl are great additions to the ANICA team, and I'm thrilled they've decided to join us as we continue on our transformational journey. Over the last couple of quarters, I've been discussing our investment in people, processes, and systems as we position ANICA for growth.

9:07 During the third quarter, we made significant progress on this front, not only with adding new talent, some of which I just described, but also with systems as we rolled out our global ERP system, SAP, across all ANACA businesses including the Parkas and Arthur Surface entities. This will give us the tools necessary to drive operational efficiency and synergy in support of our growth strategy. Before I turn the call over to Mike to review our financials for the quarter, I'd like to take a few more minutes to provide an update to our product development pipeline on slide four. As I described earlier, we fully launched our total risk platform as scheduled in September and it's now available for sale nationally. Tacticet continues to see great momentum in the U.S.

9:54 and our expansion plans for Tacticet continue with our recent launch and we're planning an additional 510 filing in 2022. We continue to make progress on our rotator cuff system with the initiation of the preclinical animal study. This system is a core part of our ASC strategy and we're excited with our progress on this project. Clinical study enrollment for both our single stage cartilage repair product Hyalafast and our second generation OA pain solution Syngal continues. Despite clinical trial enrollment challenges related to COVID, I am very pleased to report that enrollment in the Syngal pilot is on track to be completed in November. We'll continue to provide clinical trial updates as enrollment progresses as we remain focused on bringing these two exciting products into the U.S.

10:44 market. Please turn now to slide five. I'd like to put into context where we are with respect to our strategy and highlight that we're still in the early innings and navigating through COVID dynamics to position ourselves to succeed well considering the disruption being created. The remainder of 2021 and into 2022 is still part of what we call the transformation phase as we continue to invest in the business to drive scale and grow and focus on the 2021 new product launches with training on their safe and effective use as COVID lifts and we can again become more customer facing. In the second half of 2022 and in 2023, we expect to have additional new product launches targeting the ASC call point and additional system implementations to drive commercial excellence.

11:35 We're making tremendous progress here and I've already described setting us up for the next phase of growth as we move into 2023 and 24. in the 23-24 timeframe is where we expect to see the real impact of our R&D pipeline with additional 510K product launches and revenue growth accelerating. Also through 2024, we'll continue to invest in Hylafast and Singhal with ongoing clinical development to bring them to the market in the United States. As I've said before, 2024 is not the end game and is truly just the beginning for Anika as we drive accelerated growth and profitability. Now I'll turn the call over to Mike for a review of our Q3 financials, and then I'll wrap things up. Mike?

12:21 Thank you, Cheryl. I will now walk you through our results for the third quarter of 2021. Please turn to slide six. Total revenue for the third quarter of 2021 was $39.5 million. That's an increase of 25% from the third quarter last year. The year-over-year increase was due primarily to recovery from the initial impact of COVID on prior year sales, and on favorable order timing in our joint pain management product family, where revenues rose 42% to $26.2 million in the quarter. As a reminder, for year over year comparisons, ordering patterns in the prior year delayed a significant portion of last year's initial impact of the COVID pandemic on this product family from the second quarter of 2020 to the second half of last year.

13:08 Revenues in our joint pain management family, it can be lumpy from quarter to quarter based on ordering patterns, but that quarterly volatility generally stabilizes on an annual basis. The Delta variant presented headwinds for our joint preservation and restoration business in the third quarter, where revenues totaled $11.2 million, down 4% from last year. Elective procedures were limited in the quarter due to the surge of the Delta variant of COVID, which resulted in cancellation or delay of procedures as well as reduced access to potential surgeon customers with a cancellation or significant reduction of planned trade shows and medical education events. Our other revenue rose to $2.2 million in the third quarter compared with $1.5 million last year.

13:56 Our gross margin in the third quarter was 58%. That's up from 55% in the same period last year. That includes the impact of $3 million of non-cash acquisition accounting-related amortization and fair value step-up expenses associated with the 2020 acquisitions of Arthur's Surface and Parkas. Excluding these charges, adjusted gross margin was 66%, down from 70% in the same period last year, due primarily to unfavorable revenue mix and production volumes based on the timing of the impact of COVID on our results year over year. From a spending standpoint, we continue to manage our operating expenses prudently, while also intentionally investing in product development, as well as processes and systems to meet our commercial growth objectives.

14:44 Our research and development and SG&A expenses together total $25.2 million in the third quarter. That's up from $21.1 million in the same period of 2020, reflecting increased clinical trials expense, which had largely been curtailed last year at the outset of COVID, along with increased marketing and other investments in our commercial and related support organizations. As Cheryl mentioned, in the third quarter, we delivered on significant operating objectives, including the launch of the total risk solution, 510 clearance for an additional tactic set indication, as well as rollout of our ERP system to Arthrosurface and Parkis. We are pleased with the team's operational execution in support of our longer-term growth and profitability objectives. During the third quarter, we also recorded a net benefit of $3.5 million, or $1.9 million net of tax, resulting from the reduction in fair value of the contingent consideration liability associated with the acquisitions of Arthur Surface and Parkas, due primarily to a decreased likelihood that certain milestones will be met.

15:47 As of quarter end, the fair value of our remaining contingent consideration was $3.5 million, As a reminder, we evaluate the estimated fair value of contingent consideration every quarter. Our net income for the quarter was approximately $600,000, or 4 cents per diluted share, compared to a net loss of $6.4 million, or 45 cents per diluted share, in the third quarter of last year. Our net income included the benefit associated with the change in the fair value of contingent consideration. Excluding this benefit, along with the non-cash charges and adjustments described in our earnings release and online earnings presentation, we achieved adjusted net income of approximately $800,000, or five cents for diluted share, that's in line with the same period last year.

16:33 We generated adjusted EBITDA in the third quarter of $5.7 million. That's up from $4.9 million in the third quarter of last year. The increase in adjusted EBITDA was primarily due to the recovery from the initial impact of COVID offset by the incremental investments supporting our future growth and business transformation. Lastly, with regards to our cash flow and our capital structure, we have positive operating cash flows of $2.1 million for the quarter. We also made an earn-out payment of $10 million in the quarter for achievement of the regulatory milestone we detailed in last quarter's earnings call. Of that $10 million, $2.8 million was treated as a reduction in this quarter's operating cash flows. Our balance sheet remains strong with $91 million in cash and investments at the end of the third quarter.

17:22 Please turn to slide seven. Now I'd like to review our full year outlook for 2021. Due to the impact of the Delta variant, limiting elective procedures, marketing events, and overall customer access in the third quarter, and the expected impact through the remainder of the year, we are revising our revenue expectations for 2021. We now expect our fiscal 2021 revenues to grow 9 to 11% over last year. That's down from our previous guidance of 11 to 14% growth. Our faster growth continues to come from joint preservation and restoration, where we now expect revenue to grow in the upper teens percent over last year. This is down from our previous expectation of high 20s to low 30% growth, as that growth had assumed that the impact of COVID would lift in the second half of 2021.

18:12 The emergence of the Delta variant and its broad impact has significantly reduced the expected recovery in the second half of this year, as we saw in the third quarter. In joint pain management, we continue to expect mid-single-digit revenue growth over last year, in line with our previous guidance. As such, due to the volatility in ordering patterns that we saw in the third quarter, this guidance implies sequentially lower shipments in the fourth quarter. Apart from the volatility in quarterly ordering patterns by our strategic partners, our joint pain management business has stabilized on an annual basis in line with our expectations. Lastly, we expect revenue and our other product family to grow mid-single digits over 2020. With regard to the gross margin, we continue to expect adjusted gross margins for 2021 to remain consistent with 2020 in the upper 60% range.

19:04 As a reminder, our adjusted gross margin excludes the impact of Arthrosurface and Parkis acquisition-related expenses, as well as any product rationalization charges. Please see the definition of this and other non-GAAP metrics in our earnings release and online earnings presentation. With regards to spending, in 2021, we continue to prudently invest in commercial infrastructure and capabilities, including people, systems, and processes that support our transformation and will enable us to scale as we grow. as well as investing in research and development according to the product pipeline outlined during our Investor Day earlier this year. Overall, as we invest ahead of growth in support of our longer-term growth and profitability targets, we continue to expect operating expenses for 2021 to increase over 2020 as a percentage of revenue.

19:55 Due to the impact of COVID on our revenues this year, we now expect adjusted EBITDA margin in 2021 to be in the low teens. as we invest thoughtfully in driving our exciting business transformation. In summary, while COVID has presented a near-term headwind, we remain focused on driving operational execution in support of our longer-term revenue and profitability growth targets. As we detailed during our Investor Day, the transformative investments we're making today in product development and commercial execution build the foundation to drive accelerated revenue growth and profitability in the 2023 and 2024 timeframe. We are very excited about the opportunities and growth catalysts in front of us to achieve our mission and drive significant value creation for our stakeholders.

20:44 I will now turn the call back over to Cheryl.

20:47 Thanks, Mike. Please turn to slide eight, everyone. While we expect to see some short-term fluctuations, both positive and negative, as we transform the business during COVID, Annika remains focused on executing our growth story, and we remain on track to achieve our stated long-term targets. We made meaningful progress this quarter on our new product development pipeline, commercial execution, and building out the people, processes, and systems to scale this business. And these efforts will drive real value for all of our stakeholders into the future. Lastly, I'd like to note that this quarter was one marked by tremendous operational execution and the teams continuing to really come together. As always, I'd like to thank the Anika employees for their hard work through these trying times as we continue our transformation. We're happy to take your questions now.

21:39 Ladies and gentlemen, if you wish to ask a question, please signal by pressing star one on your telephone keypad. Please ensure that the mute function of your telephone is switched off to allow your signal to reach our equipment. Again, please press star one to ask a question. and we can go to Yung Lee of UBS.

21:59 All right, great. Thank you. Good evening, everyone. Thanks for taking our questions. I guess maybe to start just on the guidance, you know, it implies Q4 revenue is going to be the lowest dollar number for the year. You know, despite typically Q4 is seasonally stronger. Can you maybe talk a little bit about some of the assumptions that you have baked in and the level of conservatism there? And then, you know, maybe within that, if you can focus a little bit on the joint preservation and restoration guidance, the revenue and price.

22:49 sort of flattish number from Q3. I guess I was just wondering if you can flesh that out a little bit, given it's typically seasonally stronger as well.

23:05 Absolutely. Hi, Don. It's Mike. Let's see. First of all, so the guidance for Q4, we're giving guidance for the year and obviously with only one quarter left. that highlights Q4. Let's just take it in pieces. So the largest part of our business is joint pain management, obviously. And what we said there is that we are leaving that guidance unchanged for the year at the mid-single digits. What we saw in the third quarter of this year was higher transfer sales due to order timing from our strategic partners, including J&J MyTech. That was purely timing on their part. And so we did not change our guidance at all for the year. And so due to that same timing, those transfer shipments will go down.

23:54 So there was volatility in those orders. That does happen from time to time as our strategic partners will manage their own businesses. As it relates to that business, one of the things that we saw there was the variance in Q3 was really around the timing of those transfer shipments. We also get royalty revenue in that business based on end-user sales, and that royalty revenue was actually down low single digits, somewhat consistent with what we've seen in our direct business as well. So really the timing in Q3 was a function of just the timing of ordering patterns. So because that's the largest part of our business, it does mean that we're going to have lower sequential shipments, still larger than last year in the same quarter, but lower sequential shipments in joint pain management, and it's just due to timing.

24:50 as it relates to joint preservation. You're absolutely right. Based on our guidance, it implies that at the midpoint, we're consistent in Q4 from Q3. So as we thought about our guidance, obviously with the way that COVID's working, and we saw that in the third quarter, it's hard to lay all of this stuff out clearly. What I will say is, We would have normally expected, and we said this in our previous guidance, we would normally expect the fourth quarter to be higher. Seasonally, that's always the case. However, there's really nothing normal about how things are operating in COVID and the related staffing shortages. And so what we did is we basically said, let's presume that we're going to be flat from Q3 to Q4 at the midpoint, because the other thing that we don't know is, you know, last year at this time, Things were looking really good. And then there was the spike that happened post-holidays on COVID. And so, you know, that's a risk as well.

25:51 So we tried to factor in the risk into our guidance. You know, our previous guidance as a total company was 11% to 14%. Our current guidance is 9% to 11%. We still have line of sight to the low end of our previous guidance, absolutely. But we recognize the unpredictability of COVID. at this time. So that's what we've tried to build into our guidance for the fourth quarter.

26:17 And Yong, I would just add just to keep in mind that even in light of the COVID disruption and the staffing shortages and the unpredictability that, you know, we're still looking at upper teens percent growth, which is above market growth in that joint preservation and restoration business.

26:37 All right, great. Appreciate all the details there, Cheryl and Mike. I guess maybe just to follow up, I was wondering, can you make any comments about what you saw in October? Some of the companies in MedTech have made some comments about October trends. I was curious if you can share a little bit about what you're seeing.

27:06 Sure, Jan, it's Mike. You know, any one month obviously is only one month, and there's a lot of volatility in different regions. We did see a nice recovery in the United States in October, but we saw a pullback outside the United States in October. And I'm speaking on our direct business. So, you know, I think there are things that could make us more optimistic coming out of October from what we saw. At the same time, We've all been through this together on COVID, and it is volatile. So I think we're comfortable with the guidance that we're seeing. It's too early to see how things are going to go at this point. But so far, the business is solid. We're not seeing losses from a competitive standpoint. It's really around what's going on in the marketplace outside of us that's really driving these dynamics.

27:59 Yeah, and I would say that, you know, I think we, along with every other report you read right now, are seeing just volumes impacted, surgical volumes impacted because of the healthcare worker shortages. And, you know, trying to be predictive around where that goes right now, especially with the vaccine mandates coming online, I think is difficult. And so we just wanted to be thoughtful about that.

28:26 Okay, great. I appreciate you guys taking the questions. I'll jump back in queue. Great. Thanks, Young. The next question comes from Jim Sedati of Sedati & Co. Hi, good afternoon.

28:42 Thanks for taking the questions. I just want to be clear. This slowdown on joint preservation, you think this is a relatively short-term phenomenon? I mean, it sounds like you're still You still think your long-term goal of doubling revenue by 2024 is intact. Is that correct?

29:07 Yeah. Hi, Jim. It's Mike. Absolutely. Yeah, we are laser-focused on those longer-term targets. And we're really excited, and we tried to highlight in some of our prepared remarks around just the operational execution that's happening. We're very pleased with the wrist launch. We're pleased with the additional indication for Tacticet, the integration with Farkas and Arthrosurface with our ERP system. So all of the things that we've been saying that we were focusing on, we're really driving that execution. We obviously can't control the market in the short term. I think there is the opportunity that COVID could longer term be a benefit for us because it's accelerating the trend to the ASC, the surgery centers, So, you know, but in the near term, COVID is definitely a headwind, but it does not in any way diminish our excitement around the joint preservation business.

30:00 You know, one of the things we said at the Investor Day and we've tried to lay out is, you know, they're really, we're making the investments now that are going to be driving that accelerated growth in the 23 and 24 timeframe. And that's exactly what we expect at this point.

30:16 So it doesn't sound like you're making any change to those plans as a result of this hiccup you had in Q3 and Q4.

30:26 We're not making any changes to our long-term objectives, no. One of the things that we'll do is we're going to continue to see, as I think the other folks in this space are looking to see, how long does COVID last? How long does this continue? And we look forward to speaking to you and our investors in our year-end call, and we can see how this all plays out. So there is a near-term impact, absolutely. But in terms of the value drivers, the catalysts, our differentiated products and our focus in joint preservation in a large and growing market, none of those dynamics have changed. But definitely COVID is a near-term headwind.

31:08 And then on the balance sheet, inventory came down. pretty significantly. Is that related to the shipments to my tech, or was there something else there?

31:20 There was nothing meaningful on the inventory side. Sometimes things will swing between categories on the balance sheet if there's long-term inventory or short-term inventory between current assets and long-term, and sometimes that can lead to swings. But there's nothing meaningful changing on our inventory levels. We are watching on the supply chain side, as Cheryl mentioned, and the same things that other people are seeing, we also see as risks and we always try to make sure that we have enough inventory so that we don't experience any challenges, but it's something we're watching very closely as we go into 2022.

31:54 And then our last question is on the Salesforce. I mean, has the recent pickup in COVID cases kind of slowed you down in terms of expanding the Salesforce or what are your plans? with regards to Salesforce expansion.

32:13 Good question, Jim. This is Cheryl. I'm happy to talk about that. You know, we've talked about the fact that we really don't have specific Salesforce expansion plans from the point in time where we completed the Parkins and Arthur Surface acquisitions. It was really about integrating and optimizing the sales force, the distribution network, implementing the systems and processes to really scale the commercial execution. And that's what we've been focused on. It is going well. It's obviously been frustrating for all of us that we haven't been able to get in front of customers like we would otherwise have planned, notwithstanding COVID. getting to congresses and meetings, implementing training on the safe and effective use of our products.

33:04 All those opportunities have just been made much more difficult by the COVID dynamic. That said, we haven't stopped. We've pushed through, I think, as best as everyone has been trying to. And I think it's a broader market dynamic. But for us, it really has hampered our ability to get in front of the surgeon community to tell the ANACA story. You know, the AAOS example I gave was a perfect example of that. We have plans coming into the end of this year and into next year for significant training on the safe and effective use of our products, for presence at all of the meetings. And, you know, I think we, like everyone else, have our fingers crossed that they all go ahead the way that they're planned.

33:51 But, you know, the sales force, I would tell you, is extremely excited about the portfolio products that we've put together, about the new product launches that we've announced late last year and into this year, and the new product development pipeline and the tools that we're giving them to really get the news out about what ANIC is doing. So we're in a good place, and we look forward to kind of emerging from this dynamic that we all find ourselves in.

34:18 Yeah, I guess I lied. I do have one more. I mean, is there any reason to think that These procedures that have been postponed in Q3 and Q4 are going to be lost, or do you think that there's a fairly significant likelihood that there's some pent-up demand out there and those folks will get these procedures done at some point in 2022?

34:44 Yeah, I don't think they're lost. I mean, pain is a motivator, and these orthopedic conditions don't just magically go away. That's why people have them treated. I think the question is a matter of timing and I think the question is also a matter of bandwidth for the healthcare system because we really are seeing the impact of lack of availability of healthcare resources to actually do the surgical volumes that used to be done all the time. So I don't think these cases are lost. I think it's just a matter of timing and what the recovery curve looks like.

35:21 Okay, all right, thank you. You're welcome. Thank you. And our next question comes from Mike Petusky of Barrington Research. Good evening.

35:34 A few questions. Cheryl, did you say, I didn't quite catch it, did you say the enrollment was done in November on Singhal pilot or will be done later this month?

35:44 It will be complete by the end of this month.

35:47 Okay. Got it. All right, and then, Mike, I guess on the pain management quarter, obviously, big quarter, favorable timing, do you have any concerns around, you know, sort of another stocking issue that sort of then impacts, you know, the next couple, two, three quarters, or, you know, what are your thoughts around that?

36:11 Hi, Mike. In answer to your question, you know, that's always something that we watch, and the short answer is we do not expect that there will be excess stocking at the end of the year. One of the reasons that we and our partners, the largest of which is J&J MyTech, we're in regular contact with them and we know they need to manage their business and so if they want to buy product, they're going to buy product. but we also don't wanna have excess stock and neither do they. So we believe that the takedown in the lower shipments in the fourth quarter is sufficient based on the demand that they expect that we will not have excess inventory going into the year. Obviously with COVID, it's hard not just for us but it's hard for our partners to perfectly predict things so it's something we're watching.

37:05 Outside of the COVID dynamics, there's a lot of positive, and others across our business. But it's just uncertain at this point how COVID is going to play out. So short answer is no, we do not expect excess inventory coming out of 2021.

37:25 Can you talk about, and I know at times we've talked about this before, but just sort of refresh everybody's memory, including mine, in terms of, you know, you've got $90 million on the balance sheet. Certainly, I I suspect that you're always considering various ideas, assets that may be out there. Can you just talk about and prioritize in general capital allocation priorities? Thanks.

37:54 Yeah, absolutely. Happy to. You know, the company historically had a much higher amount of cash on the balance sheet and deployed that cash in 2020 in a few different areas. First of all, M&A was a big piece with buying Parcus and Arthrosurface, as well as investing in the commercial business, which we've done in 2020 and 2021. So we recognize the value of acquisitions to augment the strategy, but our first priority in terms of use of cash is investing in the organic business. and you've seen that this year in how we've accepted lower than historic EBITDA because we want to build the capabilities and team and all the things that enable us to scale this business.

38:40 So we are intentionally investing organically. We also recognize, as I said with Parkinson-Arthur Surface as an example, that acquisitions can be an important part of our strategy. But our expectation is that we would be doing tuck-in acquisitions. not major acquisitions at this point. You know, we have a significant opportunity in front of us. When we increase the addressable market from $1 billion to $8 billion by moving into joint preservation, we're still a very small player. And so, you know, we are focused on driving the organic and inorganic investments that will help us in the future. But those are, because of the big opportunity in front of us, our capital deployment would be for growth, first organically and secondarily with Tuckins in the near term, where they make sense. You know, valuations are always something we watch.

39:39 Okay. And I would assume that, you know, even though the company historically has done a bit of share repurchase here and there, I would assume that's not really on, not a front burner item at this point?

39:50 Absolutely. The company has done share repurchases in the past, and that's always something that the company can't consider, but we believe the primary drivers of shareholder value are, one, we've diversified our revenue by doing the acquisitions we did and the product launches. We believe that the primary way that we're going to drive shareholder value is deploying the cash for growth first. That said, if we don't see those opportunities in front of us, then we definitely recognize buybacks can be a meaningful opportunity.

40:25 Do you guys have any way to quantify the impact of and many more. So, I mean, I think that's a really hard number to quantify, frankly. I think if you think about our guidance for the year,

41:02 That guidance was based upon the opportunities that we had in front of us had COVID been lifting. We expected that COVID would have lifted in the second half of the year and before the Delta variant. That's what it looked like was going to happen. I think we were comfortable with our guidance had there not been the Delta variant. I don't know that I could quantify it, but because it had a direct impact in terms of elective procedures, it had an indirect impact in terms of shortages of staff, as well as the lack of ability at these conferences that we attended or conferences that were canceled to get in front of surgeons with our products and our capabilities. So it had a wide impact on us, but it's a hard number to quantify.

41:55 Yeah, Mike, I would just add, you know, obviously keeping track of other companies reporting out in our space. On the joint preservation and restoration piece of our business, I actually, you know, think we're either in line or better than they are. So I don't think it was an outsized impact on us by any means because I think we've got a lot of innovative products that you know, there's interest in. So I think we do find ourselves in an interesting position from that perspective, but it's very difficult to quantify.

42:33 And Cheryl, just one last thing and I'll let others get in if there are others.

42:42 and Taka Sett.

42:59 It's sort of actually putting numbers to the progress you're making, either, hey, this many new docs have tried the product or whatever. I'd love to have a sense of what great momentum, great traction actually means. I suspect I'm not the only person that feels that way. Is there anything you could add to that?

43:21 Yeah. I mean, we've talked about the fact that we're not going to break out individual products, but it's a fair question. I'll tell you that it's doubled in size this year, so we see very nice growth numbers around it. We have just opened up an additional market expansion opportunity for ourselves with this new 510K that we just got cleared that is an indication that nobody else has in the space, and a very meaningful one at that. and you heard me say there's another 510K that we plan to file next year to continue to expand off that platform. We also talked about the fact that the insufficiency fracture market, which is the first indication we launched that into, was about $100 million accessible market opportunity in the United States.

44:11 So perhaps that helps kind of size out for you.

44:15 No, it seems like an exciting opportunity. would just, you know, again, more detail, but yeah, it's absolutely exciting. All right, and that's all I've got. Thank you so much. Great. Thanks, Mike. Ladies and gentlemen, that concludes the question and answer session. I'd now like to turn the call back to Dr. Blanchard for any additional or closing remarks.

44:42 Great. Thank you all very much for your attention and interest in ANACA, and we look forward to speaking to you all Next on our Q4 call next year. Have a great night. Ladies and gentlemen, that concludes today's conference call. We thank you for your participation. You may now disconnect.

Follow Anika Therapeutics Inc. into a list and get an email when it puts out news.

Latest news releases

Companies on this call

Speakers

Mark Namaroff

Executive Director of Investor Relations and Corporate Communications

Dr. Cheryl Blanchard

President and Chief Executive Officer

Mike Levitz

Executive Vice President, Chief Financial Officer and Treasurer

Yung Lee

Analyst, UBS

Jim Sedati

Analyst, Sedati & Co.

Mike Petusky

Analyst, Barrington Research

More from Anika Therapeutics Inc.